Irinotecan is active in chemonaive patients with metastatic gastric cancer: A phase II multicentric trial

79Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

To assess the response rate and the tolerance of irinotecan as first-line therapy, 40 patients with metastatic gastric cancer received irinotecan 350 mg m-2 every 3 weeks administered as a 30 min infusion. Among the 35 patients evaluable for response, two complete and five partial responses were recorded (response rate: 20.0% (95% Cl:8.4-36.9%)). In total, 16 patients achieved stable disease and 12 progressive disease. In all, 66 percent of the patients benefited from tumour growth control. The median time to progression was 3.0 months (95% Cl: 2.3-4.4%). The median overall survival was 7.1 months (95% Cl: 5.2-9.0%). The probability of being alive at 6 months and 9 months was 61.0 and 32.4%, respectively. The median number of cycles per patient was 3 (range 1-14), and the relative dose intensity was 0.98. The most common grade 3-4 toxicities by patients were diarrhoea 20%, asthenia 10%, nausea 7.5%, vomiting 5.0%, abdominal pain 5%, neutropenia 38.5%, leucopenia 28.2%, anaemia 12.8% and thrombocytopenia 5.1%. Febrile neutropenia occurred in 12.5% of patients. These findings indicate that irinotecan is active and well tolerated in patients with metastatic gastric adenocarcinoma and warrants further evaluation in this clinical setting. © 2003 Cancer Research UK.

References Powered by Scopus

Irinotecan combined with fluorouracil compared with fluorouracil alone. as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

3141Citations
N/AReaders
Get full text

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer

2942Citations
N/AReaders
Get full text

Rising Incidence of Adenocarcinoma of the Esophagus and nGastric Cardia

2235Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Gastric cancer

1602Citations
N/AReaders
Get full text

Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data

1096Citations
N/AReaders
Get full text

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

536Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Köhne, C. H., Catane, R., Klein, B., Ducreux, M., Thuss-Patience, P., Niederle, N., … Wilke, H. J. (2003). Irinotecan is active in chemonaive patients with metastatic gastric cancer: A phase II multicentric trial. British Journal of Cancer, 89(6), 997–1001. https://doi.org/10.1038/sj.bjc.6601226

Readers over time

‘15‘16‘17‘20‘21‘22‘2300.751.52.253

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

43%

Researcher 2

29%

Professor / Associate Prof. 1

14%

Lecturer / Post doc 1

14%

Readers' Discipline

Tooltip

Medicine and Dentistry 5

63%

Biochemistry, Genetics and Molecular Bi... 2

25%

Pharmacology, Toxicology and Pharmaceut... 1

13%

Save time finding and organizing research with Mendeley

Sign up for free
0